RAF inhibitors have also been considered as a treatment for cancers with RAS mutations; however, it has been found that the inhibition of RAF in the presence of mutant RAS paradoxically activates the MAPK signaling pathway, leading to enhanced tumor growth [27,28,29]. Here, RAF1 is linked to cancer.